Digene Inheritance in RYR1 and PLEC: Myopathy Insights

Digeneic inheritance of variants in RYR1 and PLEC causing myopathy with tubular aggregates

Leena Reddy L. Reddy1, Arman Singh Grewal2, Raj P. Grewal1,3

  1. Leema Reddy Peddareddygari Dynamic Biologics Inc., 1 Deer Park drive, Monmouth Junction, New Jersey, USA, 08852
  2. Arman Singh Grewal Larner College of Medicine, University of Vermont, Vermont, USA, 05401
  3. Raji P. Grewal Dynamic Biologics Inc., 1 Deer Park drive, Monmouth Junction, New Jersey, USA, 08852; Capital Institutes for Neurosciences, 100K. Johnson Blvd North, Suite 201, Bordentown, New Jersey, USA, 08505

ABSTRACT

Despite the advances in genetic testing, a significant proportion of patients with suspected genetic myopathies remain undiagnosed. In these patients, the burden of transmission of single-gene disorders which include autosomal dominant, autosomal recessive or X-linked are investigated. However, there is a growing body of evidence that suggests that digenic inheritance may be a significant contributor to the phenotype of these patients. In this report, we present a case of a 53-year-old female with a history of neurological symptoms and a family history of weakness and fatigue. Genetic testing revealed variants in RYR1 and PLEC, which we hypothesize may be contributing to her phenotype.

Keywords

genetic myopathy, digenic inheritance, RYR1, PLEC, tubular aggregates

Introduction

Clinically genetic myopathies have been classified according to their inheritance as either autosomal recessive or autosomal dominant. However, the revolution in genetic sequencing has enabled detailed classification and diagnosis based upon the affected gene. Despite improvements in DNA sequencing technology resulting in high throughput genetic analysis, a significant portion of patients with possible genetic myopathy remain uncharacterized. It has been suggested that digenic inheritance could account for some of the patients suspected of having a genetic basis for undiagnosed neurological disorders including myopathies.

Case Study

This is a 53-year-old female with a history of neurological symptoms including weakness and fatigue. She was referred to our institution for further evaluation. The patient reported that her symptoms began in her early 30s and had progressively worsened over the years. There was no family history to suggest a myopathic or neurogenic process.

Routine blood work included a clinical core and differential was normal. A series of CK levels were performed and showed mild elevation ranging from 500-800 U/L (normal:24-204). An electromyogram (EMG) performed at an outside institution and was reported as normal. This was repeated at our institution. In our study, sensory potential testing revealed the right median, ulnar, radial, peroneal and bilateral sural nerves were normal. Motor nerve parameters in the right median, ulnar and peroneal nerves were also normal. In the right limb, there were no detectable abnormalities. A needle EMG of selected muscles showed no myopathic changes. A muscle biopsy was performed and revealed the presence of tubular aggregates.

Muscle biopsy showing tubular aggregates
Muscle biopsy showing tubular aggregates.

Genetic testing and analysis

Genetic testing was performed through a commercial laboratory using a targeted panel that included over 70 genes associated with myopathies. The patient was found to have a variant in RYR1 (c.3821C>T, p.Thr1274Met) and a variant in PLEC (c.1281G>A, p.Arg428Gln). This polymorphism has been reported in ClinVar (Variation ID: 142648) and has been classified as likely benign. The RYR1 gene is a hotspot in the RYR1 gene for pathogenic malignant hyperthermia variants. Our analysis provides strong evidence that this mutation alone is pathogenic and contributing to the disease phenotype in our patient. However, there is no family history to suggest that carrying this mutation alone can explain her phenotype. We hypothesize that there is a contribution to this phenotype from one of the other variants detected in this patient.

Discussion

In this patient, we propose the combination of the variants in RYR1 and PLEC have resulted not only in the phenotype of weakness and fatigue but also the genetic underpinnings of her muscle biopsy. Our study shows the importance of considering digenic inheritance in patients with suspected genetic myopathies when additional family members may not be available. An analysis can be performed that includes the muscle biopsy. Our study highlights the importance of genetic testing in the evaluation of patients with unexplained limb-girdle weakness.

Conclusion

In this patient, we propose the combination of the variants in RYR1 and PLEC have resulted not only in the phenotype of weakness and fatigue but also the genetic underpinnings of her muscle biopsy. Our study shows the importance of considering digenic inheritance in patients with suspected genetic myopathies when additional family members may not be available. An analysis can be performed that includes the muscle biopsy. Our study highlights the importance of genetic testing in the evaluation of patients with unexplained limb-girdle weakness.

Conflicts of Interest Statement

The authors have no conflicts of interest to declare.

Acknowledgments

No acknowledgments.

References

1. Nallamilli BRR, Chakravorty S, Kesari A, et al. Genetic landscape and novel disease mechanisms from a large LGMD cohort of 4656 patients. Ann Clin Transl Neurol. 2018;5(12):1574-1587. doi: 10.1 002/acn3.649.2. Chakravorty S, Nallamilli BRR, Khadilkar SV, et al. Clinical and Genomic Evaluation of 207 Genetic Myopathies in the Indian Subcontinent. Front Neurol. 2020; 11:559327. doi: 10.3389/fneur.2020.5 59327.

3. Töpf A, Johnson K, Bates A, et al. Sequential targeted exome sequencing of 1001 patients affected by unexplained limb-girdle weakness. Genet Med. 2020;22(9):1478-1488. doi: 10.1038/s41436-020-0840-3.

4. Peddareddygari LR, Grewal RP. Digenic inheritance in patients with undiagnosed myopathies. Medical Research Archives, 12(11) 2024. doi:10.1810 3/mra.v12i11.6046.

5. Posey JE, Harel T, Liu P, et al. Resolution of Disease Phenotypes Resulting from Multilocus Genomic Variation. N Engl J Med. 2017;376(1):21-31. doi: 10.1056/NEJMoa1516767.

6. Schäffer AA. Digenic inheritance in medical genetics. J Med Genet. 2013;50(10):641-52.
doi: 10.1136/jmedgenet-2013-101713.

7. Neuhofer CM, Prokisch H. Digenic Inheritance in Rare Disorders and Mitochondrial Disease-Crossing the Frontier to a More Comprehensive Understanding of Etiology. Int J Mol Sci. 2024;25 (9):4602. doi: 10.3390/ijms25094602.

8. Deltas C. Digenic inheritance and genetic modifiers. Clin Genet. 2018;93(3):429-438. doi: 10.1111/cge.13150.

9. Kerner G, Bouaziz M, Cobat A, et al. A genome-wide case-only test for the detection of digenic inheritance in human exomes. Proc Natl Acad Sci U S A. 2020;117(32):19367-19375. doi: 10.1073/pna s.1920650117.

10. Ng PC, Henikoff S. Predicting deleterious amino acid substitutions. Genome Res. 2001;11(5): 863-74. doi: 10.1101/gr.176601.

11. Adzhubei IA, Schmidt S, Peshkin L, et al. A method and server for predicting damaging missense mutations. Nat Methods. 2010;7(4):248-9. doi: 10.1038/nmeth0410-248.

12. Schwarz JM, Cooper DN, Schuelke M, Seelow D. MutationTaster2: mutation prediction for the deep-sequencing age. Nat Methods. 2014;11(4): 361-2. doi: 10.1038/nmeth.2890.

13. Szklarczyk D, Kirsch R, Koutrouli M, et al. The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 2023;51(D1): D638-D646. doi: 10.1093/nar/gk ac1000.

14. Ibarra M CA, Wu S, Murayama K, et al. Malignant hyperthermia in Japan: mutation screening of the entire ryanodine receptor type 1 gene coding region by direct sequencing. Anesthesiology. 2006;104(6):1146-54. doi: 10.1097/00000542-200 606000-00008.

15. Miller DM, Daly C, Aboelsaod EM, et al. Genetic epidemiology of malignant hyperthermia in the UK. Br J Anaesth. 2018;121(4):944-952. doi: 10.1016/j.bja.2018.06.028.

16. Tammaro A, Bracco A, Cozzolino S, et al. Scanning for mutations of the ryanodine receptor (RYR1) gene by denaturing HPLC: detection of three novel malignant hyperthermia alleles. Clin Chem. 2003;49(5):761-8. doi: 10.1373/49.5.761.

17. Sato K, Roesl C, Pollock N, Stowell KM. Skeletal muscle ryanodine receptor mutations associated with malignant hyperthermia showed enhanced intensity and sensitivity to triggering drugs when expressed in human embryonic kidney cells. Anesthesiology. 2013;119(1):111-8. doi: 10.1097/A LN.0b013e31828cebfe.

18. Zhang J, Felder A, Liu Y, et al. Nesprin 1 is critical for nuclear positioning and anchorage. Hum Mol Genet. 2010;19(2):329-41. doi: 10.1093/hm g/ddp499.

19. Zrelski MM, Kustermann M, Winter L. Muscle-Related Plectinopathies. Cells. 2021;10(9):2480. doi: 10.3390/cells10092480.

20. Fan Q, Gwathmey K, Du X, Seth A, Corse A. Tubular aggregate myopathy causing progressive fatiguable weakness. Pract Neurol. 2024;24(2):137-140. doi: 10.1136/pn-2023-003838.

21. Vita G, Monici MC, Owaribe K, Messina C. Expression of plectin in muscle fibers with cytoarchitectural abnormalities. Neuromuscul Disord. 2003;13(6):485-92. doi: 10.1016/s0960-8966(03)00 037-3.

22. Okazaki A, Ott J. Machine learning approaches to explore digenic inheritance. Trends Genet. 2022; 38(10):1013-1018. doi: 10.1016/j.tig.2022.04.009.

Interested in publishing your own research?
ESMED members can publish their research for free in our peer-reviewed journal.
Learn About Membership

Call for papers

Have a manuscript to publish in the society's journal?